SEC Form 4 · accession 0001144204-15-010386
DERMA SCIENCES, INC. · DSCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry Wolfenson
Officer — See Remarks
Period of report
Feb 12, 2015
Accepted (ET)
Feb 17, 2015 · 5:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000892160
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 12, 2015 | A | 3,200 | $0.00 | A | 79,292 | D | |
| Common StockF2 | Feb 12, 2015 | F | 974 | $8.83 | D | 78,318 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $13.39 | Feb 14, 2015 | A | 11,300 | A | Feb 14, 2015 | Feb 13, 2024 | Common Stock | 11,300 | 11,300 | D |
| Stock Option (right to buy)F4 | $8.83 | Feb 12, 2015 | A | 13,000 | A | Feb 12, 2015 | Feb 12, 2025 | Common Stock | 13,000 | 13,000 | D |
Explanation of responses
- F1The shares of common stock reported herein represent restricted stock units issued under the issuer's equity incentive plan in consideration of the reporting person's services to the issuer granted on February 14, 2014, subject to the issuer's satisfaction of certain performance criteria for the fiscal year ending December 31, 2014, and further subject to continued employment through the vesting date. Certain of the performance criteria for 2014 were met, resulting in the vesting of 3,200 restricted stock units.
- F2Shares withheld in connection with the vesting of 3,200 restricted stock units, previously granted pursuant to the issuer's equity incentive plan, at a closing price of $8.83, as reported herein.
- F3The options reported herein were issued under the issuer's equity incentive plan in consideration of the reporting person's services to the issuer granted on February 14, 2014, subject to the issuer's satisfaction of certain performance criteria for the fiscal year ending December 31, 2014, and further subject to continued employment through the vesting date. Certain of the performance criteria for 2014 were met, resulting in the vesting of 11,300 options.
- F4The options, granted pursuant to the issuer's equity incentive plan, vested as to 25% on the grant date and will vest as to an additional 25% on February 12 of 2016, 2017 and 2018.
Remarks
Group President, Advanced Wound Care & Pharmaceutical Development